Alan Sandler
Impact in
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Pulmonary and Respiratory Medicine top 0.02%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 104
- Lung Cancer Research Studies 44
- Cancer Immunotherapy and Biomarkers 32
- Colorectal Cancer Treatments and Studies 26
- Cancer Treatment and Pharmacology 18
-
- Lung Cancer Treatments and Mutations 68
- Lung Cancer Diagnosis and Treatment 20
- Co-authors
- Joan H. Schiller (19 shared papers)Chandra P. Belani (9 shared papers)David H. Johnson (20 shared papers)David H. Johnson (16 shared papers)Julie R. Brahmer (8 shared papers)Robert J. Gray (6 shared papers)Afshin Dowlati (3 shared papers)Michael C. Perry (2 shared papers)
- Journals
- Journal of Clinical Oncology (46 papers)Journal of Thoracic Oncology (23 papers)Lung Cancer (13 papers)Clinical Cancer Research (12 papers)Clinical Lung Cancer (6 papers)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Alan Sandler
161 papers receiving 23.5k citations
Alan Sandler's Hit Papers
Peers
Comparison fields: 5 of 129
- Oncology 13.2k
- Pulmonary and Respiratory Medicine 11.4k
- Cancer Research 2.4k
- Immunology 1.6k
- Molecular Biology 4.6k
Countries citing papers authored by Alan Sandler
This map shows the geographic impact of Alan Sandler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Sandler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Sandler more than expected).
Fields of papers citing papers by Alan Sandler
This network shows the impact of papers produced by Alan Sandler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Sandler. The network helps show where Alan Sandler may publish in the future.
Co-authors
The 25 scholars most cited alongside Alan Sandler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 163 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer Hit paper breakdown → | 2006 | 4500 |
| 2 | Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2002 | 4068 |
| 3 | Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC Hit paper breakdown → | 2018 | 2686 |
| 4 | Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial Hit paper breakdown → | 2016 | 2139 |
| 5 | Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer Hit paper breakdown → | 2003 | 2121 |
| 6 | TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2005 | 1207 |
| 7 | Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial Hit paper breakdown → | 2019 | 1170 |
| 8 | Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer Hit paper breakdown → | 2006 | 505 |
| 9 | 2005 | 452 | |
| 10 | Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial Hit paper breakdown → | 2020 | 420 |
| 11 | 2007 | 335 | |
| 12 | 2007 | 215 | |
| 13 | 2005 | 197 | |
| 14 | 2009 | 147 | |
| 15 | 2018 | 133 | |
| 16 | 2010 | 124 | |
| 17 | 1995 | 121 | |
| 18 | 2004 | 120 | |
| 19 | 2007 | 116 | |
| 20 | 2018 | 115 |
About Alan Sandler
Alan Sandler is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Epidemiology, having authored 163 papers that have together received 24.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (68 papers), Lung Cancer Research Studies (44 papers), Cancer Immunotherapy and Biomarkers (32 papers), Colorectal Cancer Treatments and Studies (26 papers), Lung Cancer Diagnosis and Treatment (20 papers), Cancer Treatment and Pharmacology (18 papers), Cancer therapeutics and mechanisms (16 papers) and Cancer Genomics and Diagnostics (10 papers). The work is most often cited by research in Oncology (13.2k citations), Pulmonary and Respiratory Medicine (11.4k citations), Cancer Research (2.4k citations), Immunology (1.6k citations) and Molecular Biology (4.6k citations). Alan Sandler has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Joan H. Schiller, Chandra P. Belani, David H. Johnson, David H. Johnson, Julie R. Brahmer, Robert J. Gray, Afshin Dowlati, Michael C. Perry, Rogério Lilenbaum and Corey J. Langer. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Lung Cancer, Clinical Cancer Research and Clinical Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.